<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071911</url>
  </required_header>
  <id_info>
    <org_study_id>TADANAC</org_study_id>
    <nct_id>NCT05071911</nct_id>
  </id_info>
  <brief_title>Targeted Axillary Dissection After Neo-adjuvant Chemotherapy</brief_title>
  <official_title>Feasability Study of a New Technique of Axillary Evaluation in Patients With Node Positive Breast Cancer Following Neo-adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently most breast cancer patients with confirmed axillary lymph node metastasis (cN1) at&#xD;
      diagnosis are candidates for neoadjuvant chemotherapy (NAC). The increased utilization of NAC&#xD;
      can be attributed to practical clinical advantages. The increasing use of NAC has, however,&#xD;
      introduced questions regarding appropriate loco-regional management, including the optimal&#xD;
      surgical approach to the axillary lymph nodes.&#xD;
&#xD;
      According to current guidelines, patients presenting with cN1 disease and treated with NAC,&#xD;
      still undergo axillary lymph node dissection (ALND). In forty percent of these patients,&#xD;
      however, we see a nodal complete pathological response (ypN0). In certain subgroups, triple&#xD;
      negative breast cancer and Her2 amplified breast cancer, this percentage is even higher. We&#xD;
      would like to lessen surgical morbidity by performing a targeted axillary dissection. We&#xD;
      place a clip in the biopsy-proven lymph node metastasis at diagnosis. After NAC, we perform a&#xD;
      dual agent sentinel node procedure and remove the clipped node during the same surgery. When&#xD;
      these lymph nodes are microscopically tumor-free, we can abolish an ALND. Targeted axillary&#xD;
      dissection after NAC for cN1 disease seems to have acceptable false negative rates in&#xD;
      previous trials. We would like to further define patients where an ALND can be safely&#xD;
      omitted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of new surgical technique TAD using Magseed</measure>
    <time_frame>90 minutes</time_frame>
    <description>Succesful retrievement of sentinel node and clipped node</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between ITC/ micrometastasis / macrometastasis in retrieved TAD nodes and number of additional lymph node metastasis in ALND</measure>
    <time_frame>Two weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAD (Targeted Axillary Dissection)</intervention_name>
    <description>Dual agent SLNB + resection of proven lymph nodes metastasis marked with clip at diagnosis</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients with confirmed axillary lymph node metastasis (cN1) at diagnosis are&#xD;
        candidates for neoadjuvant chemotherapy (NAC). Patients will be included in this study if&#xD;
        they are diagnosed with cT1-3N1M0 breast cancer, histopathologically confirmed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with cT1-3N1M0 breast cancer, histopathologically confirmed.&#xD;
&#xD;
          -  Age greater than or equal to 18 years and less than or equal to 85 years.&#xD;
&#xD;
          -  Necessity and agreement to neoadjuvant chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous surgery ipsilateral axillary or radiation ipsilateral axillary / chest.&#xD;
&#xD;
          -  Extranodal metastases M1&#xD;
&#xD;
          -  cN2-3 status&#xD;
&#xD;
          -  Breast cancer with direct invasion of chest wall and / or skin cT4&#xD;
&#xD;
          -  Disease progression (clinical /radiological) under neoadjuvant treatment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Presence of a pacemaker in the ipsilateral chest wall&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ine Luyten, MD</last_name>
    <phone>+32 2 477 9398</phone>
    <email>ine.luyten@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Borstkliniek</last_name>
    <phone>+32 2 477 6015</phone>
    <email>borstkliniek@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussel</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ine Luyten, MD</last_name>
      <phone>02 477 6015</phone>
      <email>borstkliniek@uzbrussel.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

